Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
SOLANA BEACH, Calif. , Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and
View HTML
Toggle Summary GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey SOLANA BEACH, Calif. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
SOLANA BEACH, Calif. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company’s President and CEO, David A.
View HTML
Toggle Summary Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth SOLANA BEACH, Calif. and CHICAGO , Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2022 Financial Results
Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11% SOLANA BEACH, Calif. , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on
View HTML
Toggle Summary Evoke Pharma to Report Second Quarter Results on August 10, 2022
SOLANA BEACH, Calif. , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022 , after
View HTML
Toggle Summary Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
View HTML
Toggle Summary Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use
SOLANA BEACH, Calif. , July 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Canadian Intellectual
View HTML
Toggle Summary Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
SOLANA BEACH, Calif. , June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Florida Medicaid
View HTML
Toggle Summary Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
SOLANA BEACH, Calif. , June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice
View HTML